Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALTAIR: Three ART regimens in treatment-naive HIV
NCT00335322Phase 4
Key facts
- Status
- Completed
- Start
- Feb 2007
- Primary completion
- Mar 2011
- Sponsor
- The Kirby Institute
- Modality
- Small Molecules
- Drugs
- zidovudineabacavir
- Conditions
- human immunodeficiency virus infection (HIV)
01
Overview
Phase 4, randomised, open-label trial of zidovudine and abacavir in human immunodeficiency virus infection (HIV), sponsored by The Kirby Institute. Started Feb 2007; status: completed.
02
Design
- Study design
- RandomizedOpen-label
03
Registry description
In treatment naïve HIV infected subjects, combination antiretroviral therapy including efavirenz combined with tenofovir and emtricitabine will offer non-inferior antiretroviral efficacy over 48 weeks, compared to either atazanavir boosted with ritonavir combined with tenofovir and emtricitabine or tenofovir and emtricitabine combined with zidovudine and abacavir, as assessed by change from baseline plasma HIV-1 RNA viral load.
Beyond the preview
Go deeper on NCT00335322.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00335322.